2024
F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR
Velayutham D, Bastaki K, Irfan A, Abuhaliqa M, Ghuloum S, Azeem M, Pirmohamed M, Jithesh P. F12. CLINICALLY ACTIONABLE PHARMACOGENOMIC LANDSCAPE OF PSYCHOTROPICS IN QATAR. European Neuropsychopharmacology 2024, 87: 211. DOI: 10.1016/j.euroneuro.2024.08.423.Peer-Reviewed Original ResearchClinical Pharmacogenetics Implementation ConsortiumDutch Pharmacogenetics Working GroupGenetic variationClinical Pharmacogenetics Implementation Consortium recommendationsMetabolic phenotypeWhole-genome sequencing dataImplementing PGx testingGenome sequence dataIntegration of pharmacogenomicsPharmacogenetics Working GroupAnalysis of haplotypesQatari populationPGx testingSequence dataImplementation ConsortiumUltrarapid metabolizersPharmacogenetic testingPharmacokinetic genesGenetic variantsCase of antipsychoticsPsychotropic medication responseResponse to antidepressantsResponse phenotypesCase of haloperidolChoice of therapyReview: Child Psychiatry in the Era of Genomics: The Promise of Translational Genetics Research for the Clinic
Fitzpatrick S, Antony I, Nurmi E, Fernandez T, Chung W, Brownstein C, Gonzalez-Heydrich J, Gur R, Merner A, Lázaro-Muñoz G, State M, Simon K, Hoffman E. Review: Child Psychiatry in the Era of Genomics: The Promise of Translational Genetics Research for the Clinic. JAACAP Open 2024, 3: 157-170. PMID: 40520982, PMCID: PMC12166933, DOI: 10.1016/j.jaacop.2024.06.002.Peer-Reviewed Original ResearchGenetic testingHigh-confidence risk genesPsychiatric geneticsApproaches to gene discoveryGenetic researchTranslational genetic researchClinical genetic testingEra of genomicsWhole-exome sequencingChild psychiatric disordersGenetic architectureGene discoveryClinical evaluationPharmacogenetic testingExome sequencingRisk genesGenetic underpinningsGenetic findingsEarly-onset psychosisPsychiatric disordersGenetic conceptsGeneticsLack of familiarityClinical practiceObsessive-compulsive disorder
2023
Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System
Hellwig L, Turner C, Olsen C, Libbus J, Markos B, Koehlmoos T, Haigney M, De Castro M, Saunders D. Assessing Clinical Utility of Pharmacogenetic Testing in the Military Health System. Military Medicine 2023, 189: e198-e204. PMID: 37436924, PMCID: PMC11022329, DOI: 10.1093/milmed/usad254.Peer-Reviewed Original ResearchMilitary Health SystemPharmacogenetic testingAdverse eventsCPIC guidelinesPGx testingHealth systemCurrent medication regimensPreemptive PGx testingPrimary care clinicsPreventable adverse eventsAdverse drug reactionsLarge military treatment facilitySubstantial proportionCross-sectional studyMilitary treatment facilitiesMedication metabolismPGx implementationMedication regimensRisk medicationsSerious morbidityCare clinicsMedical managementMedication listPGx resultsSingle center
2021
Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study
Ramsey CM, Lynch KG, Thase ME, Gelernter J, Kranzler HR, Pyne JM, Shih MC, Stone A, Committee C, Oslin DW. Prevalence of predicted gene-drug interactions for antidepressants in the treatment of major depressive disorder in the Precision Medicine in Mental Health Care Study. Journal Of Affective Disorders 2021, 282: 1272-1277. PMID: 33601706, DOI: 10.1016/j.jad.2021.01.034.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMental Health Care studyGene-drug interactionsDepressive disorderPGx testingAD treatmentCare studiesHealth care studiesPrecision medicineContext of pharmacotherapyPrevalence of antidepressantsUtility of PGxPrescribing practicesUS veteransPharmacogenetic testingAntidepressantsPatientsPrevious treatmentPrevalenceTreatmentDisordersPGxMedicineTest panelParticipants
2020
Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial
Oslin DW, Chapman S, Duvall SL, Gelernter J, Ingram E, Kranzler HR, Lehmann LS, Lynch JA, Lynch KG, Pyne JM, Shih MC, Stone A, Thase ME, Wray LO. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial. Contemporary Clinical Trials 2020, 101: 106247. PMID: 33316457, DOI: 10.1016/j.cct.2020.106247.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPGx test resultsRandomized clinical trialsClinical trialsPGx testingHealth care cost implicationsUtility of PGxRoutine clinical carePragmatic randomized clinical trialsEpisode of careHealth care trialsPrecision medicineHealth care providersPrecision medicine approachPatient care costsImplementation science methodsCare trialsMedication selectionPsychotropic medicationsProvider educationDepressive disorderPatient outcomesPharmacogenetic testingCare providersClinical care
2010
Pharmacogenetic Testing in the Pediatric Epileptic Population
Sander T, Marcuccilli C, Zembles T, Hines R, Lo S, North P. Pharmacogenetic Testing in the Pediatric Epileptic Population. The FASEB Journal 2010, 24: 568.16-568.16. DOI: 10.1096/fasebj.24.1_supplement.568.16.Peer-Reviewed Original ResearchAdverse drug reactionsAntiepileptic drugsSevere adverse drug reactionsABCB1 genetic variantsChronic neurologic disordersFast Real-Time PCR SystemRecurrent unprovoked seizuresAED therapyPediatric patientsUnprovoked seizuresADR riskDrug reactionsPhysician comfortNeurologic disordersEpileptic populationPharmacogenetic testingTherapeutic windowPharmacogenetic testsPatientsTherapeutic treatmentGenotype resultsReal-time PCR systemGenotyping assaysTherapyGenetic variantsValidation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing
Roper N, Storer B, Bona R, Fang M. Validation and Comparison of Pharmacogenetics-Based Warfarin Dosing Algorithms for Application of Pharmacogenetic Testing. Journal Of Molecular Diagnostics 2010, 12: 283-291. PMID: 20228265, PMCID: PMC2860463, DOI: 10.2353/jmoldx.2010.090110.Peer-Reviewed Original ResearchConceptsPharmacogenetics-based dosing algorithmDosing algorithmInternational Warfarin Pharmacogenetics ConsortiumPercentage of patientsNarrow therapeutic windowDiverse ethnic populationsMaintenance dosesProspective trialWarfarin dosesWarfarin dosingPrescribed drugsPharmacogenetic testingWarfarin metabolismIWPC algorithmClinical utilityDosing rangeTherapeutic windowWarfarinGenetic testingPatientsGenetic polymorphismsExternal validationEthnic populationsService populationCYP2C9
2003
A 5‐HT2C receptor promoter polymorphism (HTR2C − 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes
Pooley EC, Fairburn CG, Cooper Z, Sodhi MS, Cowen PJ, Harrison PJ. A 5‐HT2C receptor promoter polymorphism (HTR2C − 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2003, 126B: 124-127. PMID: 15048662, DOI: 10.1002/ajmg.b.20143.Peer-Reviewed Original ResearchConceptsObese womenWeight lossPromoter polymorphismNon-obese womenHigh triglyceride levelsInfluences weight lossAnti-obesity drugsRT-PCR studiesObese groupT statusTriglyceride levelsRisk factorsAntipsychotic drugsObesity trialsFrontal cortexPharmacogenetic testingSerotonin 5C subjectsBody weightC alleleWeight gainObesityT subjectsWomenPsychological treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply